Skip to main content
OpenTrials
Completed

NCT Number: NCT04280731

Impact of Quinoa Milk Fermented With Lactic Acid Bacteria From Foods on Human Oral and Intestinal Flora

The demand for alternatives to dairy products has increased in recent years and a lot of proposals for vegetable milk and yogurt products have taken place in the market. Quinoa is a plant from South America that has growth in popularity in recent years as many sought out nutritious and healthier eating, the herb is known for its high nutritional value. It is complete protein source containing all the essential amino acids. If this herb were fermented with probiotic bacteria, there is a potential for a product that is lactose free, gluten free and cholesterol free.

The probiotic potential of quinoa milk, fermented with food associated lactic acid bacteria will be investigated. This includes a study that examines how daily consumption of this vegetable drink changes the composition of the oral and intestinal flora. Therefore, healthy people are now seeking to participate in the study, which will be for just over 2 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Microbial Colonization Communicable Diseases Disease Attributes Infections Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kemicentrum

Lund, Skåne County, 223 62, Sweden

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Above 18 years and healthy volunteers

Exclusion criteria

  • Participants that have any kind of diseases, such as colon inflammation

Treatment and study plan

fermented quinoa

Dietary Supplement

Quinoa drink fermented with lactic acid bacteria isolated from food

Primary outcomes

  1. Survivability of the lactic acid bacteria

    Time frame: 2 weeks

    If the bacteria can be isolated in a adequate amount by cultivation on MRS broth and rogosa agar

Secondary outcomes

  1. Changes in the human microbiota

    Time frame: 2 weeks

    Changes in the saliva and stool samples by analyzes with Terminal Restriction Fragment Length polymorphism

  2. Changes in the human microbiota

    Time frame: 2 weeks

    Changes in the saliva and stool samples by quantitative polymorphic chain reaction

Sponsors and collaborators

Lead sponsor

Lund University

Other

Collaborators

  • Swedish International Development Cooperation Agency (SIDA)

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Feb 21, 2020
Registry last updated
Oct 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.